Search

Your search keyword '"Gaudy-Marqueste, C"' showing total 438 results
Start Over Author "Gaudy-Marqueste, C"
Sorry, I don't understand your search. ×
438 results on '"Gaudy-Marqueste, C"'

4. Operational classification of cutaneous squamous cell carcinomas based on unsupervised clustering of real cases by experts.

Author

Gaudy‐Marqueste, C., Grob, J. J., Garbe, C., Ascierto, P. A., Arron, S., Basset‐Seguin, N., Bohne, A. S., Lenoir, C., Dummer, R., Fargnoli, M. C., Guminski, A., Hauschild, A., Kaufmann, R., Lallas, A., Marmol, V., Migden, M., Penicaud, M., Rembielak, A., Stratigos, A., and Tagliaferri, L.

Subjects
*SQUAMOUS cell carcinoma, *CLASSIFICATION, *COMPLEX regional pain syndromes
Abstract

Background Objective Method Results Conclusion There is currently no staging system for cutaneous squamous cell carcinoma (cSCC) that is adapted to decision‐making and universally used. Experts have unconscious ability to simplify the heterogeneity of clinical situations into a few relevant groups to drive their therapeutic decisions. Therefore, we have used unsupervised clustering of real cases by experts to generate an operational classification of cSCCs, an approach that was successful for basal cell carcinomas.To generate a consensual and operational classification of cSCCs.Unsupervised independent clustering of 248 cases of cSCCs considered difficult‐to‐treat. Eighteen international experts from different specialties classified these cases into what they considered homogeneous clusters useful for management, each with freedom regarding clustering criteria. Convergences and divergences between clustering were analysed using a similarity matrix, the K‐mean approach and the average silhouette method. Mathematical modelling was used to look for the best consensual clustering. The operability of the derived classification was validated on 23 new practitioners.Despite the high heterogeneity of the clinical cases, a mathematical consensus was observed. It was best represented by a partition into five clusters, which appeared a posteriori to describe different clinical scenarios. Applicability of this classification was shown by a good concordance (94%) in the allocation of cases between the new practitioners and the 18 experts. An additional group of easy‐to‐treat cSCC was included, resulting in a six‐group final classification: easy‐to‐treat/complex to treat due to tumour and/or patient characteristics/multiple/locally advanced/regional disease/visceral metastases.Given the methodology based on the convergence of unguided intuitive clustering of cases by experts, this new classification is relevant for clinical practice. It does not compete with staging systems, but they may complement each other, whether the objective is to select the best therapeutic approach in tumour boards or to design homogeneous groups for trials. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee

Author

Michielin, O., van Akkooi, A., Lorigan, P., Ascierto, P.A., Dummer, R., Robert, C., Arance, A., Blank, C.U., Chiarion Sileni, V., Donia, M., Faries, M.B., Gaudy-Marqueste, C., Gogas, H., Grob, J.J., Guckenberger, M., Haanen, J., Hayes, A.J., Hoeller, C., Lebbé, C., Lugowska, I., Mandalà, M., Márquez-Rodas, I., Nathan, P., Neyns, B., Olofsson Bagge, R., Puig, S., Rutkowski, P., Schilling, B., Sondak, V.K., Tawbi, H., Testori, A., and Keilholz, U.

Published
2020
Full Text
View/download PDF

6. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee

Author

Keilholz, U., Ascierto, P.A., Dummer, R., Robert, C., Lorigan, P., van Akkooi, A., Arance, A., Blank, C.U., Chiarion Sileni, V., Donia, M., Faries, M.B., Gaudy-Marqueste, C., Gogas, H., Grob, J.J., Guckenberger, M., Haanen, J., Hayes, A.J., Hoeller, C., Lebbé, C., Lugowska, I., Mandalà, M., Márquez-Rodas, I., Nathan, P., Neyns, B., Olofsson Bagge, R., Puig, S., Rutkowski, P., Schilling, B., Sondak, V.K., Tawbi, H., Testori, A., and Michielin, O.

Published
2020
Full Text
View/download PDF

7. Étude nationale évaluant l’apport thérapeutique des stratégies de médecine personnalisée dans le mélanome métastatique

Author

Connell, E., primary, Gérard, E., additional, Oulès, B., additional, Brunet-Possenti, F., additional, Lamoureux, A., additional, Bonnefille, H., additional, Prey, S., additional, Carrasquilla, A., additional, Stéphane, M., additional, Kramkimel, N., additional, Lesage, C., additional, Stoebner, P.E., additional, Monestier, S., additional, Correard, F., additional, Jeanson, A., additional, Ouafik, L., additional, Gaudy-Marqueste, C., additional, Tomasini, P., additional, Charles, J., additional, Amini-Adle, M., additional, and Malissen, N., additional

Published
2023
Full Text
View/download PDF

8. Détection automatisée du mélanome. Développement d’un algorithme combinant une approche inspirée de l’analyse du dermatologue fondée sur la caractérisation de l’asymétrie du mélanome et un ensemble de réseaux de neurones à convolution

Author

Monnier, J., primary, Collenne, J., additional, Iguernaissi, R., additional, Dubuisson, S., additional, Nawaf, M., additional, Richard, M.A., additional, Grob, J.J., additional, Gaudy-Marqueste, C., additional, and Merad, D., additional

Published
2023
Full Text
View/download PDF

9. La compétition VisioMel : à la recherche d’une signature numérique prédisant le risque de récidive des mélanomes cutanés primitifs

Author

Alla, L., primary, Maubec, E., additional, Bertheau, P., additional, Khammari, A., additional, Prévot, S., additional, Dalac-Rat, S., additional, Vergier, B., additional, Battistella, M., additional, Dupuy, A., additional, Loménie, N., additional, Delaune, A., additional, Armand, L., additional, Montaudié, H., additional, Brevet, M., additional, Sattonnet, C., additional, Long-Mira, E., additional, Gaudy-Marqueste, C., additional, Quéreux, G., additional, and Staroz, F., additional

Published
2023
Full Text
View/download PDF

10. Étude d’efficacité et de tolérance en vie réelle des patients atteints de mélanome métastatique traités en première ligne par ipilimumab + nivolumab versus nivolumab

Author

Billard, K., primary, Mortier, L., additional, Dereure, O., additional, Dalac, S., additional, Montaudié, H., additional, Legoupil, D., additional, Dutriaux, C., additional, De Quatrebarbes, J., additional, Maubec, E., additional, Leccia, M.T., additional, Granel-Brocard, F., additional, Brunet-Possenti, F., additional, Arnault, J.P., additional, Gaudy-Marqueste, C., additional, Cécile, P., additional, Saiag, P., additional, L’orphelin, J.M., additional, Zehou, O., additional, Lesimple, T., additional, Allayous, C., additional, Oriano, B., additional, Dalle, S., additional, and Lebbé, C., additional

Published
2023
Full Text
View/download PDF

13. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023

Author

Peris, Ketty, Fargnoli, Maria Concetta, Kaufmann, R., Arenberger, P., Bastholt, L., Seguin, N. B., Bataille, V., Brochez, L., del Marmol, V., Dummer, R., Forsea, A. -M., Gaudy-Marqueste, C., Harwood, C. A., Hauschild, A., Holler, C., Kandolf, L., Kellerners-Smeets, N. W. J., Lallas, A., Leiter, U., Malvehy, J., Marinovic, B., Mijuskovic, Z., Moreno-Ramirez, D., Nagore, E., Nathan, P., Stratigos, A. J., Stockfleth, E., Tagliaferri, Luca, Trakatelli, M., Vieira, R., Zalaudek, Iri, Garbe, C., Peris K. (ORCID:0000-0002-5237-0463), Fargnoli M. C., Tagliaferri L. (ORCID:0000-0003-2308-0982), Zalaudek I., Peris, Ketty, Fargnoli, Maria Concetta, Kaufmann, R., Arenberger, P., Bastholt, L., Seguin, N. B., Bataille, V., Brochez, L., del Marmol, V., Dummer, R., Forsea, A. -M., Gaudy-Marqueste, C., Harwood, C. A., Hauschild, A., Holler, C., Kandolf, L., Kellerners-Smeets, N. W. J., Lallas, A., Leiter, U., Malvehy, J., Marinovic, B., Mijuskovic, Z., Moreno-Ramirez, D., Nagore, E., Nathan, P., Stratigos, A. J., Stockfleth, E., Tagliaferri, Luca, Trakatelli, M., Vieira, R., Zalaudek, Iri, Garbe, C., Peris K. (ORCID:0000-0002-5237-0463), Fargnoli M. C., Tagliaferri L. (ORCID:0000-0003-2308-0982), and Zalaudek I.

Abstract

Basal cell carcinoma (BCC) is the most common malignant tumour in white populations. Multidisciplinary experts from European Association of Dermato-Oncology (EADO), European Dermatology Forum, European Society for Radiotherapy and Oncology (ESTRO), Union Européenne des Médecins Spécialistes, and the European Academy of Dermatology and Venereology developed updated recommendations on diagnosis and treatment of BCC. BCCs were categorised into ‘easy-to-treat’ (common) and ‘difficult-to-treat’ according to the new EADO clinical classification. Diagnosis is based on clinico-dermatoscopic features, although histopathological confirmation is mandatory in equivocal lesions. The first-line treatment of BCC is complete surgery. Micrographically controlled surgery shall be offered in high-risk and recurrent BCC, and BCC located on critical anatomical sites. Topical therapies and destructive approaches can be considered in patients with low-risk superficial BCC. Photodynamic therapy is an effective treatment for superficial and low-risk nodular BCCs. Management of ‘difficult-to-treat’ BCCs should be discussed by a multidisciplinary tumour board. Hedgehog inhibitors (HHIs), vismodegib or sonidegib, should be offered to patients with locally advanced and metastatic BCC. Immunotherapy with anti-PD1 antibodies (cemiplimab) is a second-line treatment in patients with a progression of disease, contraindication, or intolerance to HHI therapy. Radiotherapy represents a valid alternative in patients who are not candidates for or decline surgery, especially elderly patients. Electrochemotherapy may be offered when surgery or radiotherapy is contraindicated. In Gorlin patients, regular skin examinations are required to diagnose and treat BCCs at an early stage. Long-term follow-up is recommended in patients with high-risk BCC, multiple BCCs, and Gorlin syndrome.

Published
2023

22. Les anticorps monoclonaux chimériques anti-ICOS 314.8 inhibent les cellules tumorales et les lymphocytes T régulateurs dans le syndrome de Sézary

Author

Amatore, F., primary, Barré, M., additional, Orlanducci, F., additional, Lopez, M., additional, Castellano, R., additional, Ram-Wolff, C., additional, Gorvel, L., additional, Goubard, A., additional, Gaudy-Marqueste, C., additional, Bagot, M., additional, Bensussan, A., additional, Delaporte, E., additional, and Olive, D., additional

Published
2022
Full Text
View/download PDF

23. 838P Patterns of response/progressive disease (PD) and management following PD with anti-PD-1 (PD1) in patients (pts) with advanced cutaneous squamous cell carcinoma (cSCC)

Author

Mo, J., primary, Bohne, A-S., additional, Gaudy Marqueste, C., additional, Della Marta, N., additional, Festino, L., additional, Chen, C., additional, Lo, S.N., additional, Park, J.J., additional, Ascierto, P.A., additional, Ladwa, R., additional, Xu, W., additional, Grob, J.J., additional, Hauschild, A., additional, Menzies, A.M., additional, Long, G.V., additional, Carlino, M.S., additional, and Pires da Silva, I., additional

Published
2022
Full Text
View/download PDF

24. Chimerized anti-ICOS 314.8 monoclonal antibodies inhibit tumor cells and regulatory T cells in patients with Sézary syndrome

Author

Amatore, FA, primary, Barre, M, additional, Orlanducci, F, additional, Lopez, M, additional, Castellano, R, additional, Ram-Wolff, C, additional, Gorvel, L, additional, Goubard, A, additional, Gaudy-Marqueste, C, additional, Bagot, M, additional, Bensussan, A, additional, Delaporte, E, additional, and Olive, D, additional

Published
2022
Full Text
View/download PDF

25. 824P Patterns of response/progression and management following progressive disease (PD) with anti-PD-(L)1 (PD(L)1) in patients (pts) with advanced Merkel cell carcinoma (MCC)

Author

Mo, J., primary, Zaremba, A., additional, Inderjeeth, A-J., additional, El Zenaity, P., additional, Li, A., additional, Wicky, A., additional, Della Marta, N., additional, Gaudy Marqueste, C., additional, Bohne, A-S., additional, Festino, L., additional, Chen, C., additional, Lo, S.N., additional, Guminski, A., additional, Michielin, O.A., additional, Xu, W., additional, Lebbe, C., additional, Sandhu, S.K., additional, Zimmer, L., additional, Carlino, M.S., additional, and Pires da Silva, I., additional

Published
2022
Full Text
View/download PDF

26. 858P Automated detection of melanoma: Comparing a convolutional neural network (CNN) approach with an algorithm assessing disorder in the pattern of pigmented lesions, intended to mimick onco-dermatologists' visual analysis

Author

Monnier, J., primary, Gouabou Foahom, A.C., additional, Serdi, M., additional, Collenne, J., additional, Iguernaissi, R., additional, Gaudy Marqueste, C., additional, Damoiseaux, J-L., additional, Grob, J.J., additional, and Merad, D., additional

Published
2022
Full Text
View/download PDF

27. 832P Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A2*02:01 patients (pts) with metastatic uveal melanoma (mUM)

Author

Dimitriou, F., primary, Hassel, J.C., additional, Orloff, M., additional, Hughes, I., additional, Kapiteijn, E., additional, Mehmi, I., additional, Montazeri, K., additional, Johnson, D.B., additional, Grover, P., additional, Gerard, C.L., additional, Simeone, E., additional, Gaudy Marqueste, C., additional, Cheng, P., additional, Long, G.V., additional, Carvajal, R.D., additional, and Dummer, R., additional

Published
2022
Full Text
View/download PDF

29. LBA46 Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab

Author

Robert, C., Milhem, M.M., Sacco, J.J., Michels, J., In, G.K., Muñoz-Couselo, E., Schadendorf, D., Beasley, G.M., Niu, J.J., Chmielowski, B., Wise-Draper, T.M., Bowles, T.L., Tsai, K.K., Lebbe, C., Gaudy Marqueste, C., Middleton, M.R., Samson, A., Zhu, J., Viana, M., and Wong, M.K.K.

Published
2024
Full Text
View/download PDF

41. Avélumab en traitement de 1re ligne des patients atteints d’un carcinome à cellules de Merkel métastatique : analyse des données en vie réelle en France à partir de bases de données de cancers rares et du Système National de Données de Santé (SNDS)

Author

Blom, A., Mortier, L., van Hille, B., Pagès, C., Samimi, M., Luciani, L., Cahuzac, C., Robert, C., Quéreux, G., Maubec, E., Maillard, C., Miotti, H., Aubin, F., Arnault, J.P., Dompmartin, A., Mansard, S., Dereure, O., Montaudié, H., Amini-Adle, M., Viguier, M., Kramkimel, N., Granel-Brocard, F., Gaudy-Marqueste, C., Zehou, O., Jeudy, G., Bernard, P., De Quatrebarbes, J., Leccia, M.T., Le Corre, Y., Beneton, N., Wierzbicka-Hainaut, E., Brunet Possenti, F., Lenormand, C., Solbes, M.N., Duval-Modeste, A.B., Kachaner, I., Lebbé, C., Dutriaux, C., and Saiag, P.

Published
2023
Full Text
View/download PDF

42. Résultats après arrêt de l’immunothérapie chez des patients atteints de mélanome avancé avec métastases cérébrales ayant reçu un protocole de double immunothérapie par ipilimumab/nivolumab : étude rétrospective nationale multicentrique

Author

Isautier, C., Lebbé, C., Mortier, L., Dalle, S., Dalac, S., Maubec, E., Montaudié, H., Gaudy-Marqueste, C., Leccia, M.T., Arnault, J.P., De Quatrebarbes, J., Dutriaux, C., Pagès-Laurent, C., Granel-Brocard, F., Saiag, P., and Lamoureux, A.

Published
2023
Full Text
View/download PDF

45. Méthodes d’administration du nivolumab dans le mélanome avancé : comparaison des effets indésirables chez des patients traités avec une dose fixe ou une dose ajustée au poids, l’étude FLATIMEL

Author

Campo Le Brun, I., Dalle, S., Mortier, L., Dereure, O., Dalac-Rat, S., Dutriaux, C., Leccia, M.T., Legoupil, D., Montaudié, H., De Quatrebarbes, J., Gaudy-Marqueste, C., Maubec, E., Saiag, P., Pagès, C., Brunet-Possenti, F., Granel-Brocard, F., Arnault, J.P., Stoebner, P.E., Aubin, F., Lesimple, T., Dupuy, A., Porcher, R., Lefevre, W., Lebbé, C., and Kempf, E.

Published
2023
Full Text
View/download PDF

47. Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition

Author

Grob, J.J., primary, Guminski, A., additional, Malvehy, J., additional, Basset‐seguin, N., additional, Bertrand, B., additional, Fernandez‐Penas, P., additional, Kaufmann, R., additional, Zalaudek, I., additional, Gaudy‐Marqueste, C., additional, Fargnoli, M.C., additional, Tagliaferri, L., additional, Fertil, B., additional, Del Marmol, V., additional, Stratigos, A., additional, Garbe, C., additional, and Peris, K., additional

Published
2021
Full Text
View/download PDF

48. Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas

Author

Grob, J.J., primary, Gaudy‐Marqueste, C., additional, Guminski, A., additional, Malvehy, J., additional, Basset‐seguin, N., additional, Bertrand, B., additional, Fernandez‐Penas, P., additional, Kaufmann, R., additional, Zalaudek, I., additional, Fargnoli, M.C., additional, Tagliaferri, L., additional, Fertil, B., additional, Del Marmol, V., additional, Stratigos, A., additional, Garbe, C., additional, and Peris, K., additional

Published
2021
Full Text
View/download PDF

49. Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition

Author

Grob, J. J. Guminski, A. Malvehy, J. Basset-seguin, N. and Bertrand, B. Fernandez-Penas, P. Kaufmann, R. Zalaudek, I and Gaudy-Marqueste, C. Fargnoli, M. C. Tagliaferri, L. and Fertil, B. Del Marmol, V Stratigos, A. Garbe, C. Peris, K.

Abstract

Background No simple classification system has emerged for `advanced basal cell carcinomas', and more generally for all difficult-to-treat BCCs (DTT-BCCs), due to the heterogeneity of situations, TNM inappropriateness to BCCs, and different approaches of different specialists. Objective To generate an operational classification, using the unconscious ability of experts to simplify the great heterogeneity of the clinical situations into a few relevant groups, which drive their treatment decisions. Method Non-supervised independent and blinded clustering of real clinical cases of DTT-BCCs was used. Fourteen international experts from different specialties independently partitioned 199 patient cases considered `difficult to treat' into as many clusters they want (

Published
2021

50. Position statement on Classification of Basal Cell Carcinomas. Part 2: EADO proposal for new operational staging system adapted to Basal Cell Carcinomas

Author

Grob, J. J. Gaudy-Marqueste, C. Guminski, A. Malvehy, J. and Basset-seguin, N. Bertrand, B. Fernandez-Penas, P. Kaufmann, R. Zalaudek, I. Fargnoli, M. C. Tagliaferri, L. Fertil, B. Del Marmol, V. Stratigos, A. Garbe, C. Peris, K.

Abstract

Background No simple staging system has emerged for basal cell carcinomas (BCCs), since they do not follow the TNM process, and practitioners failed to agree on simple clinical or pathological criteria as a basis for a classification. Operational classification of BCCs is required for decision-making, trials and guidelines. Unsupervised clustering of real cases of difficult-to-treat BCCs (DTT-BCCs; part 1) has demonstrated that experts could blindly agree on a five groups classification of DTT-BCCs based on five patterns of clinical situations. Objective Using this five patterns to generate an operational and comprehensive classification of BCCs. Method Testing practitioner’s agreement, when using the five patterns classification to ensure that it is robust enough to be used in the practice. Generating the first version of a staging system of BCCs based on pattern recognition. Results Sixty-two physicians, including 48 practitioners and the 14 experts who participated in the generation of the five different patterns of DTT-BCCs, agreed on 90% of cases when classifying 199 DTT-BCCs cases using the five patterns classification (part 1) attesting that this classification is understandable and usable in practice. In order to cover the whole field of BCCs, these five groups of DTT-BCCs were added a group representing the huge number of easy-to-treat BCCs, for which sub-classification has little interest, and a group of very rare metastatic cases, resulting in a four-stage and seven-substage staging system of BCCs. Conclusion A practical classification adapted to the specificities of BCCs is proposed. It is the first tumour classification based on pattern recognition of clinical situations, which proves to be consistent and usable. This EADO staging system version 1 will be improved step by step and tested as a decision tool and a prognostic instrument.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results